You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameThalidomide
Accession NumberDB01041  (APRD01251)
TypeSmall Molecule
GroupsApproved, Investigational, Withdrawn
DescriptionA piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action. [PubChem]
Structure
Thumb
Synonyms
(+-)-N-(2,6-dioxo-3-Piperidyl)phthalimide
(+-)-Thalidomide
(±)-N-(2,6-dioxo-3-piperidyl)phthalimide
(±)-thalidomide
1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)isoindoline
2,6-dioxo-3-phthalimidopiperidine
3-Phthalimidoglutarimide
alpha-(N-Phthalimido)glutarimide
alpha-N-Phthalylglutaramide
N-(2,6-dioxo-3-piperidyl)phthalimide
N-Phthaloylglutamimide
N-Phthalyl-glutaminsaeure-imid
N-Phthalylglutamic acid imide
Talidomida
Thalidomidum
α-(N-phthalimido)glutarimide
α-N-phthalylglutaramide
α-phthalimidoglutarimide
External Identifiers
  • NSC-527179
  • NSC-66847
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Thalidomide CelgeneCapsule50 mgOralCelgene Europe Limited  2008-04-16Not applicableEu
ThalomidCapsule50 mgOralCelgene Inc2010-11-01Not applicableCanada
ThalomidCapsule50 mg/1OralCelgene Corporation2003-06-20Not applicableUs
ThalomidCapsule100 mgOralCelgene Inc2011-02-17Not applicableCanada
ThalomidCapsule100 mg/1OralCelgene Corporation2003-06-20Not applicableUs
ThalomidCapsule200 mgOralCelgene Inc2011-02-17Not applicableCanada
ThalomidCapsule150 mg/1OralCelgene Corporation2007-03-20Not applicableUs
ThalomidCapsule150 mgOralCelgene IncNot applicableNot applicableCanada
ThalomidCapsule200 mg/1OralCelgene Corporation2003-06-20Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ConterganNot Available
DistavalNot Available
K-17Not Available
Pro-ban MNot Available
SedalisNot Available
SoftenonNot Available
TalimolNot Available
ThaledNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII4Z8R6ORS6L
CAS number50-35-1
WeightAverage: 258.2295
Monoisotopic: 258.064056818
Chemical FormulaC13H10N2O4
InChI KeyUEJJHQNACJXSKW-UHFFFAOYSA-N
InChI
InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)
IUPAC Name
2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione
SMILES
O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12
Pharmacology
IndicationFor the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.
Structured Indications
PharmacodynamicsThalidomide is an immunomodulatory agent with a spectrum of activity that is not fully characterized. Thalidomide is racemic — it contains both left and right handed isomers in equal amounts: one enantiomer is effective against morning sickness, and the other is teratogenic. The enantiomers are converted to each other in vivo. That is, if a human is given D-thalidomide or L-thalidomide, both isomers can be found in the serum. Hence, administering only one enantiomer will not prevent the teratogenic effect in humans.
Mechanism of actionIn patients with erythema nodosum leprosum (ENL) the mechanism of action is not fully understood. Available data from in vitro studies and preliminary clinical trials suggest that the immunologic effects of this compound can vary substantially under different conditions, but may be related to suppression of excessive tumor necrosis factor-alpha (TNF-a) production and down-modulation of selected cell surface adhesion molecules involved in leukocyte migration. For example, administration of thalidomide has been reported to decrease circulating levels of TNF-a in patients with ENL, however, it has also been shown to increase plasma TNF-a levels in HIV-seropositive patients. As a cancer treatment, the drug may act as a VEGF inhibitor.
TargetKindPharmacological actionActionsOrganismUniProt ID
Protein cereblonProteinyes
inhibitor
HumanQ96SW2 details
Tumor necrosis factorProteinyes
inhibitor
HumanP01375 details
Nuclear factor NF-kappa-B p105 subunitProteinyes
antagonist
HumanP19838 details
DNANucleotideyes
intercalation
Humannot applicabledetails
Fibroblast growth factor receptor 2Proteinyes
antagonist
HumanP21802 details
Prostaglandin G/H synthase 2Proteinunknown
antagonist
HumanP35354 details
Nuclear factor kappa-light-chain-enhancer of activated B cellsProteinunknownNot AvailableHumannot applicabledetails
alpha1-acid glycoproteinProtein groupunknown
binder
Humannot applicabledetails
Related Articles
AbsorptionThe absolute bioavailability has not yet been characterized in human subjects due to its poor aqueous solubility. In studies of both healthy volunteers and subjects with Hansen’s disease, the mean time to peak plasma concentrations (Tmax) ranged from 2.9 to 5.7 hours indicating that thalidomide is slowly absorbed from the gastrointestinal tract.
Volume of distributionNot Available
Protein binding55% and 66% for the (+)R and (−)S enantiomers, respectively.
Metabolism

Thalidomide itself does not appear to be hepatically metabolized to any large extent, but appears to undergo non-enzymatic hydrolysis in plasma to multiple metabolites. Thalidomide may be metabolized hepatically by enzymes of the cytochrome P450 enzyme system. The end product of metabolism, phthalic acid, is excreted as a glycine conjugate.

SubstrateEnzymesProduct
Thalidomide
cis, trans-5'-HydroxythalidomideDetails
Thalidomide
5-HydroxythalidomideDetails
Thalidomide
Thalidomide arene oxideDetails
Thalidomide arene oxide
Not Available
5-HydroxythalidomideDetails
5-Hydroxythalidomide
5,6-dihydroxythalidomideDetails
Thalidomide
Not Available
4-phthalimidoglutaramic acidDetails
Thalidomide
Not Available
2-phthalimidoglutaramic acidDetails
2-phthalimidoglutaramic acid
Not Available
2-phthalimidoglutaric acidDetails
4-phthalimidoglutaramic acid
Not Available
2-phthalimidoglutaric acidDetails
Thalidomide
Not Available
alpha-(o-carboxybenzamido)glutarimideDetails
4-phthalimidoglutaramic acid
Not Available
4-(o-carboxybenzamido)glutaramic acidDetails
2-phthalimidoglutaramic acid
Not Available
2-(o-carboxybenzamido)glutaramic acidDetails
alpha-(o-carboxybenzamido)glutarimide
Not Available
2-(o-carboxybenzamido)glutaramic acidDetails
4-(o-carboxybenzamido)glutaramic acid
Not Available
2-(o-carboxybenzamido)glutaric acidDetails
4-(o-carboxybenzamido)glutaramic acid
Not Available
2-(o-carboxybenzamido)glutaric acidDetails
2-(o-carboxybenzamido)glutaramic acid
Not Available
2-(o-carboxybenzamido)glutaric acidDetails
Route of eliminationThalidomide itself has less than 0.7% of the dose excreted in the urine as unchanged drug.
Half lifeThe mean half-life of elimination ranges from approximately 5 to 7 hours following a single dose and is not altered upon multiple dosing.
ClearanceNot Available
ToxicityThe R-configuration and the S-configuration are more toxic individually than the racemic mixture. The LD50 could not be established in mice for racemic thalidomide, whereas LD50 values for the R and S configurations are reported to be 0.4 to 0.7 g/kg and 0.5 to 1.5 g/kg, respectively.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 Tetrafluoroethane1,1,1,2 Tetrafluoroethane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Investigational
7-Nitroindazole7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Experimental
AbirateroneThe serum concentration of Thalidomide can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Thalidomide.Approved
AcepromazineAcepromazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Vet Approved
AceprometazineAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Acetazolamide.Approved, Vet Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Thalidomide.Approved
adipiplonadipiplon may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Investigational
AgomelatineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Thalidomide.Approved
AlfaxaloneAlfaxalone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Vet Approved
AlfentanilAlfentanil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Aliskiren is combined with Thalidomide.Approved, Investigational
AlphacetylmethadolAlphacetylmethadol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Experimental, Illicit
AlprazolamAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit, Investigational
ALT-110The risk or severity of adverse effects can be increased when Thalidomide is combined with ALT-110.Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Thalidomide.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Thalidomide.Approved
AmiodaroneThe metabolism of Thalidomide can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational
AmitriptylineAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Thalidomide.Approved
AmobarbitalAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
AmoxapineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
AmperozideAmperozide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Experimental
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Thalidomide.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Thalidomide.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Thalidomide.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Thalidomide.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Thalidomide.Approved
AprepitantThe metabolism of Thalidomide can be increased when combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational
ArmodafinilThe metabolism of Thalidomide can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Thalidomide.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Thalidomide.Approved, Investigational
ArticaineArticaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
AsenapineAsenapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Thalidomide.Approved
AzaperoneAzaperone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Vet Approved
AzelastineAzelastine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Thalidomide.Approved
AzithromycinThe metabolism of Thalidomide can be decreased when combined with Azithromycin.Approved
BaclofenBaclofen may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Thalidomide.Experimental
BarbitalBarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Thalidomide.Approved
BazedoxifeneBazedoxifene may increase the thrombogenic activities of Thalidomide.Approved, Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Thalidomide.Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Thalidomide.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Thalidomide.Approved
BenperidolBenperidol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Investigational
BenzocaineBenzocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
Benzyl alcoholBenzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Thalidomide.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Thalidomide.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Thalidomide.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Thalidomide.Approved
BortezomibThe metabolism of Thalidomide can be decreased when combined with Bortezomib.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Thalidomide.Approved
BrexpiprazoleBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
BromazepamBromazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Thalidomide.Approved, Investigational
BrompheniramineBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
BrotizolamBrotizolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Thalidomide.Approved
BupivacaineBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational
BuprenorphineBuprenorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit, Investigational, Vet Approved
BuspironeBuspirone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational
ButabarbitalButabarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
ButacaineButacaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Vet Approved
ButalbitalButalbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
ButambenButamben may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
ButethalButethal may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
ButorphanolButorphanol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit, Vet Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Thalidomide.Approved
CaffeineThe metabolism of Thalidomide can be decreased when combined with Caffeine.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Thalidomide.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Thalidomide.Approved
CapecitabineThe metabolism of Thalidomide can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Thalidomide.Approved
CarbamazepineCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Thalidomide.Approved
CarbinoxamineCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
CarfentanilCarfentanil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Illicit, Vet Approved
CarisoprodolCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Thalidomide.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Thalidomide.Approved, Investigational
CDX-110The risk or severity of adverse effects can be increased when Thalidomide is combined with CDX-110.Investigational
CeritinibThe serum concentration of Thalidomide can be increased when it is combined with Ceritinib.Approved
CetirizineCetirizine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
Chloral hydrateChloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Thalidomide can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
ChlormezanoneChlormezanone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Withdrawn
ChloroprocaineChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Thalidomide.Approved, Vet Approved
ChlorotrianiseneChlorotrianisene may increase the thrombogenic activities of Thalidomide.Withdrawn
ChlorphenamineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
ChlorpromazineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Vet Approved
ChlorprothixeneChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Thalidomide.Approved
ChlorzoxazoneChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
CholecalciferolThe metabolism of Thalidomide can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Thalidomide.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Thalidomide.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Thalidomide.Approved
CimetidineThe metabolism of Thalidomide can be decreased when combined with Cimetidine.Approved
CinchocaineCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Vet Approved
CitalopramThe metabolism of Thalidomide can be decreased when combined with Citalopram.Approved
ClemastineClemastine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Thalidomide.Approved
ClidiniumClidinium may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
ClobazamClobazam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Thalidomide.Approved, Investigational
clomethiazoleclomethiazole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Investigational
ClomipramineClomipramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Vet Approved
ClonazepamClonazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
ClonidineClonidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
ClorazepateClorazepate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
ClotrimazoleThe metabolism of Thalidomide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
CocaineCocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
CodeineCodeine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Thalidomide.Approved, Investigational
Conjugated Equine EstrogensConjugated Equine Estrogens may increase the thrombogenic activities of Thalidomide.Approved
CyclizineCyclizine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
CyclobenzaprineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Thalidomide.Approved, Investigational
CyclosporineThe metabolism of Thalidomide can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
Cyproterone acetateThe serum concentration of Thalidomide can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Thalidomide can be decreased when it is combined with Dabrafenib.Approved
DantroleneDantrolene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Thalidomide.Approved
DapiprazoleDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Dapoxetine.Investigational
Darbepoetin alfaDarbepoetin alfa may increase the thrombogenic activities of Thalidomide.Approved, Investigational
DeferasiroxThe serum concentration of Thalidomide can be increased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Thalidomide can be decreased when combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Thalidomide.Approved
deramciclanederamciclane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Investigational
DesfluraneDesflurane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
DesipramineDesipramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Thalidomide.Approved
DesloratadineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational
DesogestrelDesogestrel may increase the thrombogenic activities of Thalidomide.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Desvenlafaxine.Approved
DetomidineDetomidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Vet Approved
DexamethasoneDexamethasone may increase the dermatologic adverse activities of Thalidomide.Approved, Investigational, Vet Approved
DexbrompheniramineDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
DexmedetomidineDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Vet Approved
DextromoramideDextromoramide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit, Withdrawn
DezocineDezocine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
DiazepamDiazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Thalidomide.Approved
DienestrolDienestrol may increase the thrombogenic activities of Thalidomide.Approved
DienogestDienogest may increase the thrombogenic activities of Thalidomide.Approved
DiethylstilbestrolDiethylstilbestrol may increase the thrombogenic activities of Thalidomide.Approved
DifenoxinDifenoxin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
DigitoxinDigitoxin may decrease the cardiotoxic activities of Thalidomide.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Thalidomide.Approved
DihydrocodeineDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
DihydroetorphineDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Experimental, Illicit
DihydromorphineDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Experimental, Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Thalidomide.Approved
DimenhydrinateDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Thalidomide.Approved
DiphenhydramineDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
DiphenoxylateDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Thalidomide.Approved
DisulfiramThe metabolism of Thalidomide can be decreased when combined with Disulfiram.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Thalidomide.Approved, Investigational
DoramectinDoramectin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Vet Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Thalidomide.Approved
DoxepinDoxepin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Vet Approved
DPDPEDPDPE may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Vet Approved
DrospirenoneDrospirenone may increase the thrombogenic activities of Thalidomide.Approved
DrotebanolDrotebanol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Experimental, Illicit
DuloxetineThalidomide may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineDyclonine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
EcgonineEcgonine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Experimental, Illicit
ECGONINE METHYL ESTERECGONINE METHYL ESTER may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Experimental
EcopipamEcopipam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Investigational
EfavirenzEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Thalidomide.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Thalidomide.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Thalidomide.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Thalidomide.Approved
EnfluraneEnflurane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Vet Approved
EntacaponeEntacapone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Thalidomide.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Thalidomide.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Thalidomide.Approved
ErythropoietinErythropoietin may increase the thrombogenic activities of Thalidomide.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Thalidomide is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Thalidomide can be decreased when combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Thalidomide.Approved
EsomeprazoleThe metabolism of Thalidomide can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamEstazolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
EstradiolEstradiol may increase the thrombogenic activities of Thalidomide.Approved, Investigational, Vet Approved
EstramustineEstramustine may increase the thrombogenic activities of Thalidomide.Approved
EstriolEstriol may increase the thrombogenic activities of Thalidomide.Approved, Vet Approved
Estrogens, esterifiedEstrogens, esterified may increase the thrombogenic activities of Thalidomide.Approved
EstroneEstrone may increase the thrombogenic activities of Thalidomide.Approved
Estrone sulfateEstrone sulfate may increase the thrombogenic activities of Thalidomide.Approved
EszopicloneEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Thalidomide.Approved
EthanolEthanol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
EthchlorvynolEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit, Withdrawn
Ethinyl EstradiolEthinyl Estradiol may increase the thrombogenic activities of Thalidomide.Approved
EthosuximideEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
EthotoinEthotoin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
Ethyl carbamateEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Withdrawn
Ethyl loflazepateEthyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
EthylmorphineEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
Ethynodiol diacetateEthynodiol diacetate may increase the thrombogenic activities of Thalidomide.Approved
EtidocaineEtidocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
EtifoxineEtifoxine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Withdrawn
EtizolamEtizolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
EtomidateEtomidate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
EtonogestrelEtonogestrel may increase the thrombogenic activities of Thalidomide.Approved, Investigational
EtoperidoneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Etoperidone.Approved
EtorphineEtorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Illicit, Vet Approved
EtravirineThe metabolism of Thalidomide can be decreased when combined with Etravirine.Approved
EzogabineEzogabine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
FelbamateFelbamate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Thalidomide.Approved, Investigational
FencamfamineFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Thalidomide.Approved
FentanylFentanyl may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit, Investigational, Vet Approved
FexofenadineFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Thalidomide.Approved
FingolimodThalidomide may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FlibanserinFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
FloxuridineThe metabolism of Thalidomide can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Thalidomide can be decreased when combined with Fluconazole.Approved
FludiazepamFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
FlunarizineFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
FlunitrazepamFlunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
FluorouracilThe metabolism of Thalidomide can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Thalidomide can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Withdrawn
FluphenazineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
FlurazepamFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
FluspirileneFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
Fluticasone PropionateFluticasone Propionate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
FluvastatinThe metabolism of Thalidomide can be decreased when combined with Fluvastatin.Approved
FluvoxamineFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Thalidomide.Approved
FosphenytoinFosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
FospropofolFospropofol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Thalidomide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Thalidomide is combined with G17DT.Investigational
GabapentinGabapentin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational
gabapentin enacarbilgabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
Gamma Hydroxybutyric AcidGamma Hydroxybutyric Acid may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
GemfibrozilThe metabolism of Thalidomide can be decreased when combined with Gemfibrozil.Approved
GenisteinGenistein may increase the thrombogenic activities of Thalidomide.Investigational
GepironeGepirone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Investigational
GestodeneGestodene may increase the thrombogenic activities of Thalidomide.Approved
GI-5005The risk or severity of adverse effects can be increased when Thalidomide is combined with GI-5005.Investigational
GlutethimideGlutethimide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
GuanfacineGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational
HalazepamHalazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit, Withdrawn
HaloperidolHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
HalothaneHalothane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Vet Approved
HeroinHeroin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
HexestrolHexestrol may increase the thrombogenic activities of Thalidomide.Withdrawn
HexobarbitalHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Thalidomide.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Thalidomide.Approved, Vet Approved
HydrocodoneHydrocodone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Thalidomide.Approved
HydromorphoneHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
IloperidoneIloperidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Thalidomide.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Thalidomide.Investigational
ImipramineImipramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
IndalpineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Thalidomide.Approved
IndinavirThe metabolism of Thalidomide can be decreased when combined with Indinavir.Approved
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Thalidomide.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Thalidomide is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Thalidomide is combined with INGN 225.Investigational
IrbesartanThe metabolism of Thalidomide can be decreased when combined with Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Thalidomide.Approved
IsofluraneIsoflurane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Vet Approved
IsoniazidThe metabolism of Thalidomide can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Thalidomide.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Thalidomide.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Thalidomide.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Thalidomide.Approved
KetamineKetamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Vet Approved
KetazolamKetazolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
KetobemidoneKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
KetoconazoleThe metabolism of Thalidomide can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Thalidomide.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Thalidomide.Approved
LamotrigineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Leflunomide.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Thalidomide.Approved, Investigational
LevetiracetamLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Thalidomide.Approved
LevobupivacaineLevobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
LevocabastineLevocabastine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
LevocetirizineLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
LevodopaLevodopa may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
Levomethadyl AcetateLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Thalidomide is combined with Levomilnacipran.Approved
LevonorgestrelLevonorgestrel may increase the thrombogenic activities of Thalidomide.Approved, Investigational
LevorphanolLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Thalidomide.Approved, Investigational
LidocaineLidocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Thalidomide.Approved, Investigational
LithiumLithium may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
LofentanilLofentanil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Thalidomide.Approved, Investigational
LopinavirThe metabolism of Thalidomide can be increased when combined with Lopinavir.Approved
LoratadineLoratadine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
LorazepamLorazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
LosartanThe metabolism of Thalidomide can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Thalidomide can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineLoxapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
Lu AA21004Lu AA21004 may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Investigational
LuliconazoleThe serum concentration of Thalidomide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Thalidomide can be decreased when it is combined with Lumacaftor.Approved
LurasidoneLurasidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
LynestrenolLynestrenol may increase the thrombogenic activities of Thalidomide.Investigational
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Thalidomide.Approved, Investigational
MaprotilineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Thalidomide.Approved
MeclizineMeclizine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
MedetomidineMedetomidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Vet Approved
Medroxyprogesterone acetateMedroxyprogesterone acetate may increase the thrombogenic activities of Thalidomide.Approved, Investigational
MelatoninMelatonin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Nutraceutical, Vet Approved
MelperoneMelperone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
MepivacaineMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Vet Approved
MeprobamateMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
MesoridazineMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
MestranolMestranol may increase the thrombogenic activities of Thalidomide.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Thalidomide.Withdrawn
MetaxaloneMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
MethadoneMethadone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
Methadyl AcetateMethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
MethallenestrilMethallenestril may increase the thrombogenic activities of Thalidomide.Experimental
MethapyrileneMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Withdrawn
MethaqualoneMethaqualone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Thalidomide.Approved
MethocarbamolMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Vet Approved
MethohexitalMethohexital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
MethotrimeprazineMethotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
Methoxy polyethylene glycol-epoetin betaMethoxy polyethylene glycol-epoetin beta may increase the thrombogenic activities of Thalidomide.Approved
MethoxyfluraneMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Vet Approved
MethsuximideMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Thalidomide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Thalidomide.Approved
MethylphenobarbitalMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Thalidomide.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Thalidomide.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Thalidomide.Approved, Investigational
MetyrosineThalidomide may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Thalidomide can be decreased when combined with Mexiletine.Approved
MidazolamMidazolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
MifepristoneThe serum concentration of Thalidomide can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Thalidomide is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Thalidomide.Approved
MirtazapineMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
MoclobemideThe metabolism of Thalidomide can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Thalidomide can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Thalidomide.Approved
MolindoneMolindone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
MorphineMorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Thalidomide.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Thalidomide.Approved
NalbuphineNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
NatalizumabThe risk or severity of adverse effects can be increased when Thalidomide is combined with Natalizumab.Approved, Investigational
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Thalidomide.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Thalidomide is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Thalidomide can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Thalidomide.Approved, Investigational
NevirapineThe metabolism of Thalidomide can be decreased when combined with Nevirapine.Approved
NicardipineThe metabolism of Thalidomide can be decreased when combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Thalidomide.Approved
NicotineThe metabolism of Thalidomide can be decreased when combined with Nicotine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Thalidomide.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Thalidomide.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Thalidomide.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Thalidomide.Approved
NitrazepamNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Thalidomide.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Thalidomide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Thalidomide.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Thalidomide.Approved
Nitrous oxideNitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Vet Approved
NorelgestrominNorelgestromin may increase the thrombogenic activities of Thalidomide.Approved
NorgestimateNorgestimate may increase the thrombogenic activities of Thalidomide.Approved
NorgestrelNorgestrel may increase the thrombogenic activities of Thalidomide.Approved
NormethadoneNormethadone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
NortriptylineNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Thalidomide.Approved
OlanzapineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Thalidomide.Approved, Investigational
OlopatadineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
OmeprazoleThe metabolism of Thalidomide can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
OpiumOpium may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
OrphenadrineThalidomide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantOsanetant may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Investigational
OsimertinibThe serum concentration of Thalidomide can be decreased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Thalidomide.Approved
OxazepamOxazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
OxetacaineOxetacaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Investigational
OxprenololOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
OxybuprocaineOxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
OxycodoneOxycodone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit, Investigational
OxymorphoneOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Thalidomide.Approved, Vet Approved
PaliperidonePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
PamidronateThalidomide may increase the nephrotoxic activities of Pamidronate.Approved
PantoprazoleThe metabolism of Thalidomide can be decreased when combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Thalidomide.Approved
ParaldehydeThalidomide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Thalidomide can be increased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Thalidomide.Approved, Investigational
PentazocinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Vet Approved
PentobarbitalPentobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
PerazinePerazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Thalidomide.Approved
PerospironePerospirone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
PerphenazinePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
PethidinePethidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Thalidomide.Approved
PhenobarbitalPhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Thalidomide.Approved
PhenoxyethanolPhenoxyethanol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Thalidomide.Approved
PhenytoinPhenytoin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Thalidomide.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Thalidomide.Approved, Investigational
PimozidePimozide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Thalidomide.Approved
PipamperonePipamperone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
PipotiazinePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
PiritramidePiritramide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Investigational
PizotifenPizotifen may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
Polyestradiol phosphatePolyestradiol phosphate may increase the thrombogenic activities of Thalidomide.Approved
PomalidomidePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
PramipexoleThalidomide may increase the sedative activities of Pramipexole.Approved, Investigational
PramocainePramocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
PrazepamPrazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Thalidomide.Approved
PregabalinPregabalin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit, Investigational
PregnanolonePregnanolone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Investigational
PrilocainePrilocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
PrimidonePrimidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Vet Approved
ProcaineProcaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Vet Approved
ProchlorperazineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Vet Approved
PromazinePromazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Vet Approved
PromestrienePromestriene may increase the thrombogenic activities of Thalidomide.Investigational
PromethazinePromethazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
ProparacaineProparacaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Vet Approved
PropofolPropofol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Vet Approved
PropoxycainePropoxycaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Thalidomide.Approved, Investigational
ProtriptylineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
PSD502PSD502 may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Investigational
PyrimethamineThe metabolism of Thalidomide can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamQuazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit
QuetiapineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Thalidomide.Approved, Investigational
QuinestrolQuinestrol may increase the thrombogenic activities of Thalidomide.Approved
QuinineThe metabolism of Thalidomide can be decreased when combined with Quinine.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Thalidomide.Approved
RacloprideRaclopride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Investigational
RamelteonRamelteon may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Thalidomide.Approved
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Thalidomide.Approved
RemifentanilRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
RemoxiprideRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Withdrawn
ReserpineReserpine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
RifampicinThe metabolism of Thalidomide can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Thalidomide can be increased when combined with Rifapentine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Thalidomide.Approved
RisperidoneRisperidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational
RitanserinRitanserin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Thalidomide.Approved
RomifidineRomifidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Vet Approved
RopiniroleThalidomide may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
RotigotineThalidomide may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Thalidomide.Approved
S EquolS Equol may increase the thrombogenic activities of Thalidomide.Investigational
S-EthylisothioureaS-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Thalidomide.Approved
Sage 547Sage 547 may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Investigational
ScopolamineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
SecobarbitalSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Vet Approved
SecoisolariciresinolSecoisolariciresinol may increase the thrombogenic activities of Thalidomide.Investigational
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Thalidomide.Approved, Investigational, Vet Approved
SertindoleSertindole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Withdrawn
SertralineThe metabolism of Thalidomide can be decreased when combined with Sertraline.Approved
SevofluraneSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Vet Approved
SildenafilThe metabolism of Thalidomide can be decreased when combined with Sildenafil.Approved, Investigational
SimeprevirThe metabolism of Thalidomide can be decreased when combined with Simeprevir.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Thalidomide.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Thalidomide.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
SorafenibThe metabolism of Thalidomide can be decreased when combined with Sorafenib.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Thalidomide.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Thalidomide.Approved
SRP 299The risk or severity of adverse effects can be increased when Thalidomide is combined with SRP 299.Investigational
StiripentolStiripentol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Thalidomide.Approved
SufentanilSufentanil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational
SulfadiazineThe metabolism of Thalidomide can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Thalidomide can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Thalidomide can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideSulpiride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
SuvorexantSuvorexant may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may increase the thrombogenic activities of Thalidomide.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may increase the thrombogenic activities of Thalidomide.Approved
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Thalidomide.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Thalidomide.Approved, Investigational
TandospironeTandospirone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
TasimelteonTasimelteon may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Thalidomide.Approved, Investigational
TemazepamTemazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
TenofovirThe metabolism of Thalidomide can be decreased when combined with Tenofovir.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Thalidomide.Approved
TeriflunomideThe serum concentration of Thalidomide can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
TetracaineTetracaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Vet Approved
TetrodotoxinTetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Investigational
TG4010The risk or severity of adverse effects can be increased when Thalidomide is combined with TG4010.Investigational
TheophyllineThe metabolism of Thalidomide can be decreased when combined with Theophylline.Approved
ThiamylalThiamylal may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Vet Approved
ThiopentalThiopental may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Vet Approved
ThioridazineThioridazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
ThiothixeneThiothixene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
TiagabineTiagabine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
TiaprideTiapride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Investigational
TiboloneTibolone may increase the thrombogenic activities of Thalidomide.Approved
TicagrelorThe metabolism of Thalidomide can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Thalidomide can be decreased when combined with Ticlopidine.Approved
TiletamineTiletamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Vet Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Thalidomide.Approved
TizanidineTizanidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
TofacitinibThalidomide may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazolineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Thalidomide can be decreased when combined with Tolbutamide.Approved
TolcaponeTolcapone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Withdrawn
TopiramateTopiramate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Thalidomide.Approved
TramadolTramadol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Thalidomide.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Experimental
TranylcypromineTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Thalidomide.Approved, Investigational
TrazodoneTrazodone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Thalidomide is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Thalidomide.Approved
TriazolamTriazolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
TrifluoperazineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
TriflupromazineTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Vet Approved
TrimethoprimThe metabolism of Thalidomide can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
TriprolidineTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
Uc1010Uc1010 may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Investigational
Valproic AcidValproic Acid may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational
ValsartanThe metabolism of Thalidomide can be decreased when combined with Valsartan.Approved, Investigational
VemurafenibThe serum concentration of Thalidomide can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Thalidomide.Approved
VigabatrinVigabatrin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
VoriconazoleThe metabolism of Thalidomide can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
XylazineXylazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Vet Approved
ZafirlukastThe metabolism of Thalidomide can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonZaleplon may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Illicit, Investigational
ZeranolZeranol may increase the thrombogenic activities of Thalidomide.Vet Approved
ZiconotideZiconotide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Thalidomide is combined with Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
ZolazepamZolazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Vet Approved
Zoledronic acidThe risk or severity of adverse effects can be increased when Thalidomide is combined with Zoledronic acid.Approved
ZolpidemZolpidem may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
ZonisamideZonisamide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational
ZopicloneZopiclone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
ZotepineZotepine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved
ZuclopenthixolZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Jamshed Shah, “Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs.” U.S. Patent US20030139451, issued July 24, 2003.

US20030139451
General ReferencesNot Available
External Links
ATC CodesL04AX02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (180 KB)
MSDSDownload (58.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9775
Blood Brain Barrier+0.9382
Caco-2 permeable-0.5651
P-glycoprotein substrateSubstrate0.5301
P-glycoprotein inhibitor INon-inhibitor0.5115
P-glycoprotein inhibitor IINon-inhibitor0.8951
Renal organic cation transporterNon-inhibitor0.8179
CYP450 2C9 substrateNon-substrate0.7904
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.5309
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9378
BiodegradationNot ready biodegradable0.8838
Rat acute toxicity3.3039 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9769
hERG inhibition (predictor II)Non-inhibitor0.8735
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
CapsuleOral100 mg/1
CapsuleOral100 mg
CapsuleOral150 mg
CapsuleOral150 mg/1
CapsuleOral200 mg/1
CapsuleOral200 mg
CapsuleOral50 mg/1
CapsuleOral50 mg
Prices
Unit descriptionCostUnit
Thalomid 28 50 mg capsule Disp Pack4372.47USD disp
Thalomid 200 mg capsule277.5USD capsule
Thalomid 150 mg capsule260.61USD capsule
Thalomid 100 mg capsule243.73USD capsule
Thalomid 50 mg capsule150.15USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2157288 No2005-11-082014-02-24Canada
CA2505964 No2009-07-282023-11-13Canada
US6045501 No1998-08-282018-08-28Us
US6235756 No1993-03-012013-03-01Us
US6315720 No2000-10-232020-10-23Us
US6561976 No1998-08-282018-08-28Us
US6561977 No2000-10-232020-10-23Us
US6755784 No2000-10-232020-10-23Us
US6869399 No2000-10-232020-10-23Us
US6908432 No1998-08-282018-08-28Us
US7141018 No2000-10-232020-10-23Us
US7230012 No2003-12-092023-12-09Us
US7435745 No1997-11-032017-11-03Us
US7874984 No1998-08-282018-08-28Us
US7959566 No2000-10-232020-10-23Us
US8204763 No1998-08-282018-08-28Us
US8315886 No2000-10-232020-10-23Us
US8589188 No1998-08-282018-08-28Us
US8626531 No2000-10-232020-10-23Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point270 °CPhysProp
water solubility545 mg/L (at 25 °C)BUDAVARI,S ET AL. (1996)
logP0.33HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility2.55 mg/mLALOGPS
logP0.42ALOGPS
logP0.016ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)11.59ChemAxon
pKa (Strongest Basic)-6.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area83.55 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity64.32 m3·mol-1ChemAxon
Polarizability24.42 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0wba-4900000000-77362eaf27267f59650dView in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as isoindolones. These are aromatic polycyclic compounds that an isoindole bearing a ketone.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIsoindoles and derivatives
Sub ClassIsoindolines
Direct ParentIsoindolones
Alternative Parents
Substituents
  • Isoindolone
  • Isoindole
  • Piperidinedione
  • Piperidinone
  • Dicarboximide
  • Delta-lactam
  • 3-aminopiperidine
  • Benzenoid
  • Piperidine
  • Carboxylic acid imide, n-unsubstituted
  • Carboxylic acid imide
  • Tertiary amine
  • Lactam
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as MEIS2. Normal degradation of key regulatory proteins is required for normal limb outgrowth and expression of the fibroblast growth factor FGF8. May play a role in memory and learning by regulating the assembly an...
Gene Name:
CRBN
Uniprot ID:
Q96SW2
Molecular Weight:
50545.375 Da
References
  1. Zhu YX, Kortuem KM, Stewart AK: Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013 Apr;54(4):683-7. doi: 10.3109/10428194.2012.728597. Epub 2012 Sep 28. [PubMed:22966948 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Tumor necrosis factor receptor binding
Specific Function:
Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs ...
Gene Name:
TNF
Uniprot ID:
P01375
Molecular Weight:
25644.15 Da
References
  1. Richardson P, Hideshima T, Anderson K: Thalidomide in multiple myeloma. Biomed Pharmacother. 2002 May;56(3):115-28. [PubMed:12046682 ]
  2. Fu LM, Fu-Liu CS: Thalidomide and tuberculosis. Int J Tuberc Lung Dis. 2002 Jul;6(7):569-72. [PubMed:12102294 ]
  3. Enomoto N, Takei Y, Hirose M, Ikejima K, Miwa H, Kitamura T, Sato N: Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-alpha production. Gastroenterology. 2002 Jul;123(1):291-300. [PubMed:12105857 ]
  4. Rajkumar SV: Thalidomide in the treatment of multiple myeloma. Expert Rev Anticancer Ther. 2001 Jun;1(1):20-8. [PubMed:12113124 ]
  5. Vescovo G, Ravara B, Angelini A, Sandri M, Carraro U, Ceconi C, Dalla Libera L: Effect of thalidomide on the skeletal muscle in experimental heart failure. Eur J Heart Fail. 2002 Aug;4(4):455-60. [PubMed:12167383 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Turk BE, Jiang H, Liu JO: Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7552-6. [PubMed:8755512 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Transcriptional repressor activity, rna polymerase ii transcription regulatory region sequence-specific binding
Specific Function:
NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-co...
Gene Name:
NFKB1
Uniprot ID:
P19838
Molecular Weight:
105355.175 Da
References
  1. Yasui K, Kobayashi N, Yamazaki T, Agematsu K: Thalidomide as an immunotherapeutic agent: the effects on neutrophil-mediated inflammation. Curr Pharm Des. 2005;11(3):395-401. [PubMed:15723633 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
4. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
yes
Actions
intercalation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Stephens TD, Bunde CJ, Fillmore BJ: Mechanism of action in thalidomide teratogenesis. Biochem Pharmacol. 2000 Jun 15;59(12):1489-99. [PubMed:10799645 ]
  2. Shoji A, Kuwahara M, Ozaki H, Sawai H: Modified DNA aptamer that binds the (R)-isomer of a thalidomide derivative with high enantioselectivity. J Am Chem Soc. 2007 Feb 7;129(5):1456-64. [PubMed:17263432 ]
  3. Stephens TD, Fillmore BJ: Hypothesis: thalidomide embryopathy-proposed mechanism of action. Teratology. 2000 Mar;61(3):189-95. [PubMed:10661908 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein tyrosine kinase activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an...
Gene Name:
FGFR2
Uniprot ID:
P21802
Molecular Weight:
92024.29 Da
References
  1. Eichholz A, Merchant S, Gaya AM: Anti-angiogenesis therapies: their potential in cancer management. Onco Targets Ther. 2010 Jun 24;3:69-82. [PubMed:20616958 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Horrobin DF: A low toxicity maintenance regime, using eicosapentaenoic acid and readily available drugs, for mantle cell lymphoma and other malignancies with excess cyclin D1 levels. Med Hypotheses. 2003 May;60(5):615-23. [PubMed:12710892 ]
  2. Hada M, Mizutari K: [A case report of metastatic pancreatic cancer that responded remarkably to the combination of thalidomide, celecoxib and irinotecan]. Gan To Kagaku Ryoho. 2004 Sep;31(9):1407-10. [PubMed:15446566 ]
  3. Payvandi F, Wu L, Haley M, Schafer PH, Zhang LH, Chen RS, Muller GW, Stirling DI: Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell Immunol. 2004 Aug;230(2):81-8. [PubMed:15598423 ]
  4. Wiedmann MW, Caca K: Molecularly targeted therapy for gastrointestinal cancer. Curr Cancer Drug Targets. 2005 May;5(3):171-93. [PubMed:15892618 ]
  5. Du GJ, Lin HH, Xu QT, Wang MW: Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis. Vascul Pharmacol. 2005 Aug;43(2):112-9. [PubMed:15982930 ]
  6. Kim JH, Scialli AR: Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol Sci. 2011 Jul;122(1):1-6. doi: 10.1093/toxsci/kfr088. Epub 2011 Apr 19. [PubMed:21507989 ]
7. Nuclear factor kappa-light-chain-enhancer of activated B cells
Kind
Protein
Organism
Human
Pharmacological action
unknown
References
  1. Kim JH, Scialli AR: Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol Sci. 2011 Jul;122(1):1-6. doi: 10.1093/toxsci/kfr088. Epub 2011 Apr 19. [PubMed:21507989 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Components:
NameUniProt IDDetails
Alpha-1-acid glycoprotein 1P02763 Details
Alpha-1-acid glycoprotein 2P19652 Details
References
  1. Turk BE, Jiang H, Liu JO: Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7552-6. [PubMed:8755512 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Wang B, Zhou SF: Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218. [PubMed:19754423 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 07, 2016 02:37